KSKristin Salamon

Kristin Salamon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristin Salamon has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Urinary Antimicrobial Peptides and Cytokines as Biomarkers for Recurrent Urinary Tract Infection in Children and Adolescents

    by Guillermo Yepes, Hancong Chloe Tang, Natalie Holdsworth, Kristin Salamon, Laura Schwartz, Christina Ching, Steve Rust, John David Spencer

    Background: Recurrent urinary tract infection (rUTI) is a major diagnostic and management challenge. Dysregulated innate immune responses, including antimicrobial peptides and cytokines, may underlie UTI susceptibility. This study investigates whether urinary concentrations of antimicrobial peptides and cytokines differ in children and adolescents with a history of rUTI and whether they can accurately classify rUTI status. Methods: Urine samples were collected from 42 girls and adolescent females with a history of rUTI and 37 matched healthy controls. Concentrations of antimicrobial peptides (alpha-defensins 1-3, beta-defensin 1, cathelicidin, secretory leukocyte protease inhibitor, lipocalin 2, and ribonuclease 7) and cytokines (interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor alpha) were quantified using enzyme-linked immunosorbent assays. A logistic regression model with variable selection was developed to classify rUTI participants based on urinary biomarkers and clinical factors. Results: Compared to controls, participants with rUTI had lower concentrations of beta-defensin 1, cathelicidin, and ribonuclease 7, and higher concentrations of alpha-defensins 1-3, lipocalin 2, and secretory leukocyte protease inhibitor. Cytokine concentrations, including interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor alpha, were elevated in the rUTI group. The predictive model demonstrated high accuracy, with an area under the receiver operating curve of 0.97 and a prevalence-adjusted area under the precision-recall curve of 0.94. Conclusions: Girls and adolescent females with rUTI exhibit a distinct urinary immune profile characterized by dysregulated antimicrobial peptides and elevated proinflammatory cytokines. A predictive model integrating these biomarkers with clinical features accurately classified rUTI status, supporting their potential utility as diagnostic tools for pediatric UTI.


  • Open Access

    Repurposing HDAC inhibitors to enhance ribonuclease 4 and 7 expression and reduce urinary tract infection

    by Laura Schwartz, M. Skye Bochter, Aaron Simoni, Kristin Bender, Juan de Dios Ruiz Rosado, Israel Cotzomi-Ortega, Yuriko I. Sanchez-Zamora, Brian Becknell, Sarah Linn, Birong Li, et al.

    With the emergence of antibiotic-resistant bacteria, innovative approaches are needed for the treatment of urinary tract infections. Boosting antimicrobial peptide expression may provide an alternative to antibiotics. Here, we developed reporter cell lines and performed a high-throughput screen of clinically used drugs to identify compounds that boost ribonuclease 4 and 7 expression (RNase 4 and 7), peptides that have antimicrobial activity against antibiotic-resistant uropathogens. This screen identified histone deacetylase (HDAC) inhibitors as effective RNase 4 and RNase 7 inducers. Validation studies in primary human kidney and bladder cells confirmed pan-HDAC inhibitors as well as the HDAC class I inhibitor, MS-275, induce RNase 4 and RNase 7 to protect human kidney and bladder cells from uropathogenic Escherichia coli . When we administered MS-275 to mice, RNase 4 and 7 expression increased and mice were protected from acute transurethral E. coli challenge. In support of this mechanism, MS-275 treatment increased acetylated histone H3 binding to the RNASE4 and RNASE7 promoters. Overexpression and knockdown of HDAC class I proteins identified HDAC3 as a primary regulator of RNase 4 and 7. These results demonstrate the protective effects of enhancing RNase 4 and RNase 7, opening the door to repurposing medications as antibiotic conserving therapeutics for urinary tract infection.